Otsuka vs. Sun Pharma reshapes Australian patent term extension rules for pharmaceutical formulations. The Full Court limits PTE to active ingredients per se, leaving controlled‑release aripiprazole depot products outside the extension regime and impacting lifecycle strategies.
Seagen vs. Daiichi Sankyo marks a major setback for broad biologics genus claims as the Federal Circuit overturned Seagen’s $41.8M jury verdict, invalidating US10808039B2 for lack of written description and enablement under the post Amgen v. Sanofi standard.
In the case of Allergan vs. Sandoz, the United States Court of Appeals for the Federal Circuit (CAFC) has invalidated a key Allergan patent covering the use of prostaglandin F (PGF) analogs for hair growth, handing a significant win to generic manufacturer Sandoz Inc.
Recently, The High Court of Delhi delivered a judgment in FMC v. Natco, a case between FMC Corporation and others (“FMC group”) and Natco Pharma Limited (“Natco”).
On Nov 5, 2025, the Patents Court handed down an important interim injunction decision in Dr Reddy’s Laboratories (UK) Ltd v Boehringer Ingelheim International GmbH, neutral citation EWHC 2834 (Pat). Michael Tappin KC, sitting as a Deputy Judge, granted interim relief restraining Dr Reddy’s from dealing in empagliflozin (the active in Jardiance) in the UK … Read more
In the case Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., the Federal Circuit upheld a Patent Trial and Appeal Board decision invalidating claims related to Merck’s multiple sclerosis drug Mavenclad, an oral formulation of the compound Cladribine. Merck Serono S.A. v. Hopewell Pharma Ventures, Inc. – Basic Details: Merck Serono S.A. v. Hopewell Pharma … Read more
A recent Delhi High Court judgment in Zeria Pharmaceutical Co. Ltd. vs. The Controller of Patents (C.A.(COMM.IPD-PAT) 452/2022) delivers a message to the pharmaceutical industry: a higher yield and greater purity are not enough to secure a patent in India. Zeria’s patent application for a novel intermediate compound was rejected by the Indian Patent Office, … Read more
UK Court of Appeal Judgment on Dapagliflozin Patent UK Court of Appeal Judgment: Dapagliflozin Patent In a recent landmark judgment, the UK Court of Appeal upheld the High Court’s April 2025 decision invalidating the UK equivalent patent of EP1506211B1 (expired on May 14, 2023) for Dapagliflozin and its associated Supplementary Protection Certificate (SPC) (Expiry Date: … Read more
